Business Description

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines. Headquartered in Watertown, Massachusetts, with research operations in Sweden, the company utilizes its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to match therapies to patients based on protein signatures rather than genetic mutations. Its lead clinical candidate, ACR-368, is a targeted small molecule inhibitor being evaluated in Phase 2 trials for endometrial, ovarian, and urothelial cancers.

Everything on Acrivon Therapeutics, Inc.

YoY growth —
Operating margin —
Direction —
Gross margin —
Net margin —

Leadership & board

View leadership ↗
Peter Blume-Jensen — Co-Founder, Chief Executive Officer, President & Chairman View full profile ↗ Kristina Masson — Co-Founder, Executive Vice President, Business Operations & Director View full profile ↗ Eric Devroe — Chief Operating Officer View full profile ↗ Mary-Alice Miller — Chief Legal Officer View full profile ↗ Adam Levy — Chief Financial Officer View full profile ↗ Mansoor Raza Mirza — Chief Medical Officer View full profile ↗ Erick Gamelin — Chief Development Officer View full profile ↗ Sharon Shacham — Director View full profile ↗ Derek DiRocco — Director View full profile ↗ Michael Tomsicek — Director View full profile ↗ Charles Baum — Director View full profile ↗ Ivana Magovčević-Liebisch — Director View full profile ↗ Santhosh Palani — Director View full profile ↗

Named Competitors

AstraZenecaMerckBristol Myers SquibbZentalis PharmaceuticalsRepare TherapeuticsDebiopharmSchrodingerSierra OncologyBoundless BioSentinel OncologyImpact TherapeuticsAprea TherapeuticsBioCity BiopharmaHUYA BiomedicinesQilu Pharma +3 more

Customer Concentration

Acrivon is a pre-revenue, clinical-stage biopharmaceutical company. It has no products approved for commercial sale and has not generated product revenue, so it has no commercial customers or customer concentration.

Recent SEC Filings

2026-06-17 Leadership change (directors/officers) (+1 more) View filing ↗
2026-05-13 Reported quarterly results View filing ↗
2026-03-19 Reported quarterly results (+1 more) View filing ↗
2026-03-02 Terminated a material agreement View filing ↗
2026-02-27 Regulation FD disclosure View filing ↗
2026-01-08 Regulation FD disclosure View filing ↗
2026-01-08 Reported quarterly results (+2 more) View filing ↗
2025-11-13 Reported quarterly results View filing ↗
2025-09-05 Regulation FD disclosure View filing ↗
2025-08-13 Reported quarterly results View filing ↗
2025-06-13 Shareholder vote results View filing ↗
2025-05-14 Reported quarterly results View filing ↗

More Companies

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.